SLC5A2 and type 1 diabetes mellitus: SGLT2 inhibitors, possibly by reducing apoptosis and improving sensitivity to incretins secreted by beta cells, can lead to an increase in mRNA expression, MafA and Pdx1, and an increase in the active level of glucagon‐like peptide‐1, which improves blood sugar homeostasis in T1DM.3, 14